Trimeris, Inc. (NASDAQ:TRMS) has released the sales results for the first quarter of 2010. The company reported sales of $24.4 million for the quarter, 12% less than the year ago period’s sales of $27.8 million. 2009’s fourth quarter was 4% higher at $25.5 million. The company’s FUZEON net sales for the United States and Canada were $7.2 million. FUZEON sales for the year ago period and the previous quarter were $10.0 million and $9.0 million, respectively. FUZEON Sales outside of the United States and Canada were $17.3 million, $17.8 million, and $16.5 million for the 2010 first quarter, 2009 first quarter, and 2009 fourth quarter, respectively.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Trimeris, Inc. (Trimeris) is a biopharmaceutical company. The Company is engaged in the commercialization of a class of antiviral drug treatments called fusion inhibitors. Fusion inhibitors prevent viral fusion, a process by which viruses attach to, penetrate and infect host cells. By inhibiting the fusion process of particular types of viruses, like the human immunodeficiency virus (HIV), its commercial product, FUZEON, and its development-stage compound, TRI-1144, offer a mechanism of action to treat and prevent the transmission of HIV. FUZEON has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
